Prevention of Viral Hepatitis and HIV Infection among People Who Inject Drugs: A Systematic Review and Meta-Analysis

Yen-Ju Chen,Yu-Chen Lin,Meng-Tien Wu,Jenn-Yuan Kuo,Chun-Hsiang Wang

DOI: https://doi.org/10.3390/v16010142

2024-01-19

Viruses

Abstract:This study aimed to explore the current evidence on preventing blood-borne virus infections among people who inject drugs (PWID). We conducted a comprehensive search across three databases (PubMed, Embase, Cochrane Library) for relevant articles published in English between 2014 and 2023. We followed the Preferred Reporting Items for Systematic Reviews and Meta Analysis (PRISMA) guidelines, assessed the quality of the paper using the revised Cochrane Risk of Bias Tool (ROB 2), and conducted a meta-analysis using RevMan 5.3. Completing the harm reduction program (HRP) participation and receiving all three vaccine doses resulted in a 28% reduction in the risk of HBV infection (OR: 0.72, 95% CI: 0.37–1.42). Various interventions increased the willingness of PWIDs to undergo HCV treatment (OR: 5.91, 95% CI: 2.46–14.24) and promoted treatment adherence (OR: 15.04, 95% CI: 2.80–80.61). Taking PrEP, participating in HRP, and modifying risky behaviors were associated with a 33% reduction in the risk of HIV infection (OR: 0.67, 95% CI: 0.61–0.74). Conducting referrals, providing counseling, and implementing antiretroviral therapy resulted in a 44% reduction in the risk of viral transmission (OR: 0.56, 95% CI: 0.47–0.66). Co-infection may potentially compromise effectiveness, so it is important to consider drug resistance.

virology

What problem does this paper attempt to address?

This paper aims to explore the current evidence for preventing blood - borne virus infections (such as viral hepatitis and HIV infection) among people who inject drugs (PWID). The study evaluated the effectiveness of various interventions through systematic review and meta - analysis methods to reduce the virus infection rate in these high - risk groups.

Specifically, the paper focuses on the following issues:
1. **Prevention of HBV infection**: The study found that completing participation in a harm reduction program (HRP) and receiving all three doses of vaccination can reduce the risk of HBV infection by 28% (OR: 0.72, 95% CI: 0.37 - 1.42, p - value = 0.34).

2. **Prevention of HCV infection**: Through various interventions, such as peer outreach, mobile health, financial incentives, on - site HCV care, and vertically integrated HCV testing, the willingness of PWID to receive HCV treatment can be significantly increased (OR: 5.91, 95% CI: 2.46 - 14.24, p - value < 0.0001), treatment compliance can be promoted (OR: 15.04, 95% CI: 2.80 - 80.61, p - value = 0.0002), and the possibility of HCV cure can be increased (OR: 1.53, 95% CI: 0.81 - 2.89, p - value = 0.19).

3. **Prevention of HIV infection**: For PWID who are not infected with HIV, through peer education, harm reduction programs, needle - exchange programs, and health counseling, the risk of HIV infection can be significantly reduced. For PWID who are already infected with HIV, through referral, counseling, and the use of antiretroviral therapy (ART), virus replication can be effectively inhibited and the risk of virus transmission can be reduced. Overall, the results show that taking PrEP, participating in HRP, and changing high - risk behaviors can reduce the risk of HIV infection by 33% (OR: 0.67, 95% CI: 0.61 - 0.74, p - value < 0.00001). In addition, through referral, providing counseling, and implementing ART, the risk of virus transmission can be reduced by 44% (OR: 0.56, 95% CI: 0.47 - 0.66, p - value < 0.00001).

In conclusion, this paper mainly explores how to prevent viral hepatitis and HIV infection among people who inject drugs through various interventions, provides comprehensive evidence of current research, and evaluates the effectiveness of these interventions.